Biotech investments, including initial public offerings and mergers and acquisitions, ramped up this year. With patent cliffs looming, pharma companies are seeking partnerships to explore new therapeutic options and innovation.
At Paragon, we use biology to accelerate scientific breakthroughs to treat and cure disease. With that focus, we seek out areas of unmet needs and identify the best science to find therapeutic solutions. One area of focus that we excel in is neurology.
Hear more from David Brill, MD, SVP, Portfolio Management.
